Back

A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant

Morange, P.-E.; Peiretti, F.; Gourhant, L.; Proust, C.; Sapirella, G.; Pulcrano-Nicolas, A.-S.; Stefanucci, L.; Lacroix, R.; Ibrahim-Kosta, M.; Lemarie, C.; Frontini, M.; Alessi, M.-C.; Tregouet, D.-A.; Couturaud, F.

2020-05-26 hematology
10.1101/2020.05.23.20101402
Show abstract

Rare variants outside the classical coagulation cascade might cause rare inherited thrombosis. We aimed to identify the variant(s) causing venous thromboembolism (VTE) in a family with multiple relatives affected with unprovoked VTE and no thrombophilia defects. We identified by whole exome sequencing an extremely rare Arg to Gln variant (R89Q) in the Microtubule Associated Serine/Threonine Kinase 2 (MAST2) gene that segregates with VTE in the family. Free-tissue factor pathway inhibitor (f-TFPI) plasma levels were significantly decreased in affected family members compared to healthy relatives. Conversely, plasminogen activator inhibitor-1 (PAI-1) levels were significantly higher in affected members than in healthy relatives. RNA sequencing analysis of RNA interference experimental data conducted in endothelial cells revealed that, of the 13,387 detected expressed genes, 2,354 have their level of expression modified by MAST2 knockdown, including SERPINE1 coding for PAI-1 and TFPI. In HEK293 cells overexpressing the MAST2R289Q variant, TFPI and SERPINE1 promoter activities were respectively lower and higher than in cells overexpressing the MAST2 wild type allele. This study identifies a novel thrombophilia-causing R89Q variant in the MAST2 gene that is here proposed as a new molecular player in the etiology of VTE by interfering with hemostatic balance of endothelial cells. Author SummaryVenous thromboembolism (VTE) is a multifactorial disease in which the genetic burden. We here present the case of a French family with multiple relatives affected with unprovoked VTE (i.e. that occurred in the absence of clinical risk factors) in which no thrombophilia defects had been identified. Adopting a whole exome sequencing approach, we identified an extremely rare variant located in the Microtubule-associated serine/threonine-protein kinase-2 (MAST2) gene that perfectly segregates with the VTE phenotype and that interferes with hemostatic balance of endothelial cells. Our results pave the way for adding MAST2 to the list of genes to be sequenced and looked for in thrombophilia families with unprovoked VTE.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Blood
based on 14 papers
Top 0.1%
22.7%
2
PLOS ONE
based on 1737 papers
Top 44%
11.5%
3
British Journal of Haematology
based on 12 papers
Top 0.3%
7.2%
4
Blood Advances
based on 16 papers
Top 0.3%
5.7%
5
Scientific Reports
based on 701 papers
Top 34%
5.3%
50% of probability mass above
6
Journal of Thrombosis and Haemostasis
based on 10 papers
Top 0.1%
5.1%
7
Leukemia
based on 11 papers
Top 0.4%
3.3%
8
Atherosclerosis
based on 16 papers
Top 1%
2.8%
9
Frontiers in Medicine
based on 99 papers
Top 6%
2.6%
10
Biomedicines
based on 21 papers
Top 1%
2.1%
11
JCI Insight
based on 63 papers
Top 3%
2.1%
12
eLife
based on 262 papers
Top 14%
2.1%
13
Nature Genetics
based on 72 papers
Top 6%
1.8%
14
Science Advances
based on 52 papers
Top 2%
1.5%
15
Journal of Clinical Investigation
based on 50 papers
Top 2%
1.5%
16
PLOS Computational Biology
based on 141 papers
Top 7%
1.5%
17
Nature Communications
based on 483 papers
Top 34%
1.4%
18
The American Journal of Human Genetics
based on 77 papers
Top 6%
0.9%
19
Gut
based on 17 papers
Top 2%
0.8%
20
Signal Transduction and Targeted Therapy
based on 10 papers
Top 1.0%
0.8%
21
The Journal of Immunology
based on 19 papers
Top 2%
0.8%
22
Journal of Infection
based on 64 papers
Top 7%
0.8%
23
Cell
based on 28 papers
Top 3%
0.8%
24
Frontiers in Physiology
based on 18 papers
Top 3%
0.8%
25
Frontiers in Immunology
based on 140 papers
Top 7%
0.8%
26
EBioMedicine
based on 21 papers
Top 2%
0.8%
27
Science Translational Medicine
based on 40 papers
Top 5%
0.8%
28
European Journal of Human Genetics
based on 25 papers
Top 3%
0.8%